| Year |
Citation |
Score |
| 2020 |
Yahata T, Ibrahim AA, Hirano KI, Muguruma Y, Naka K, Hozumi K, Vaughan DE, Miyata T, Ando K. Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells. Haematologica. PMID 32001531 DOI: 10.3324/Haematol.2019.230227 |
0.335 |
|
| 2019 |
Sun T, Ghosh AK, Eren M, Miyata T, Vaughan DE. PAI-1 contributes to homocysteine-induced cellular senescence. Cellular Signalling. 109394. PMID 31472244 DOI: 10.1016/J.Cellsig.2019.109394 |
0.362 |
|
| 2019 |
Miller RA, Harrison DE, Astle CM, Bogue MA, Brind J, Fernandez E, Flurkey K, Javors M, Ladiges W, Leeuwenburgh C, Macchiarini F, Nelson J, Ryazanov AG, Snyder J, Stearns TM, ... Vaughan DE, et al. Glycine supplementation extends lifespan of male and female mice. Aging Cell. e12953. PMID 30916479 DOI: 10.1111/Acel.12953 |
0.33 |
|
| 2019 |
Rai R, Sun T, Ramirez V, Lux E, Eren M, Vaughan DE, Ghosh AK. Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis. Journal of Cellular and Molecular Medicine. PMID 30710427 DOI: 10.1111/Jcmm.14162 |
0.325 |
|
| 2019 |
Ridker PM, Vaughan DE. Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors. Journal of Thrombosis and Thrombolysis. 1: 251-257. PMID 10608002 DOI: 10.1007/Bf01060734 |
0.341 |
|
| 2017 |
Rai R, Ghosh AK, Eren M, Mackie AR, Levine DC, Kim SY, Cedernaes J, Ramirez V, Procissi D, Smith LH, Woodruff TK, Bass J, Vaughan DE. Downregulation of the Apelinergic Axis Accelerates Aging, whereas Its Systemic Restoration Improves the Mammalian Healthspan. Cell Reports. 21: 1471-1480. PMID 29117554 DOI: 10.1016/J.Celrep.2017.10.057 |
0.672 |
|
| 2017 |
Rai R, Verma SK, Kim D, Ramirez V, Lux E, Li C, Sahoo S, Wilsbacher LD, Vaughan DE, Quaggin SE, Ghosh AK. A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis. Epigenetics. 0. PMID 28933600 DOI: 10.1080/15592294.2017.1370173 |
0.32 |
|
| 2017 |
Eren M, Place AT, Thomas PM, Flevaris P, Miyata T, Vaughan DE. PAI-1 is a critical regulator of FGF23 homeostasis. Science Advances. 3: e1603259. PMID 28924605 DOI: 10.1126/Sciadv.1603259 |
0.373 |
|
| 2017 |
Flevaris P, Khan SS, Eren M, Schuldt AJ, Shah SJ, Lee DC, Gupta S, Shapiro A, Burridge P, Ghosh AK, Vaughan DE. PAI-1 Controls Cardiomyocyte TGF-β and Cardiac Fibrosis. Circulation. PMID 28588076 DOI: 10.1161/Circulationaha.117.028145 |
0.318 |
|
| 2017 |
Vaughan DE, Rai R, Khan SS, Eren M, Ghosh AK. Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 28572158 DOI: 10.1161/Atvbaha.117.309451 |
0.347 |
|
| 2016 |
Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, Vaughan DE. A small molecule inhibitor of PAI-1 protects against Doxorubicin-induced cellular senescence: molecular basis. Oncotarget. PMID 27736799 DOI: 10.18632/Oncotarget.12494 |
0.346 |
|
| 2016 |
Flevaris P, Vaughan D. The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis. Seminars in Thrombosis and Hemostasis. PMID 27556351 DOI: 10.1055/S-0036-1586228 |
0.343 |
|
| 2015 |
Pelisch N, Dan T, Ichimura A, Sekiguchi H, Vaughan DE, van Ypersele de Strihou C, Miyata T. Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis. Plos One. 10: e0124510. PMID 25915660 DOI: 10.1371/Journal.Pone.0124510 |
0.327 |
|
| 2015 |
Boe AE, Eren M, Morales-Nebreda L, Murphy SB, Budinger GR, Mutlu GM, Miyata T, Vaughan DE. Nitric oxide prevents alveolar senescence and emphysema in a mouse model. Plos One. 10: e0116504. PMID 25756287 DOI: 10.1371/Journal.Pone.0116504 |
0.32 |
|
| 2014 |
Eren M, Boe AE, Klyachko EA, Vaughan DE. Role of plasminogen activator inhibitor-1 in senescence and aging. Seminars in Thrombosis and Hemostasis. 40: 645-51. PMID 25173500 DOI: 10.1055/S-0034-1387883 |
0.313 |
|
| 2014 |
Eren M, Boe AE, Murphy SB, Place AT, Nagpal V, Morales-Nebreda L, Urich D, Quaggin SE, Budinger GR, Mutlu GM, Miyata T, Vaughan DE. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proceedings of the National Academy of Sciences of the United States of America. 111: 7090-5. PMID 24778222 DOI: 10.1073/Pnas.1321942111 |
0.379 |
|
| 2014 |
Bagai K, Muldowney JA, Song Y, Wang L, Bagai J, Artibee KJ, Vaughan DE, Malow BA. Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea. Sleep. 37: 359-67. PMID 24497664 DOI: 10.5665/Sleep.3414 |
0.323 |
|
| 2014 |
Agirbasli M, Eren M, Yasar S, Delil K, Goktay F, Oner ET, Vaughan DE. Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo. Journal of Thrombosis and Thrombolysis. 38: 50-6. PMID 24197654 DOI: 10.1007/S11239-013-1021-X |
0.325 |
|
| 2013 |
Boe AE, Eren M, Murphy SB, Kamide CE, Ichimura A, Terry D, McAnally D, Smith LH, Miyata T, Vaughan DE. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation. 128: 2318-24. PMID 24092817 DOI: 10.1161/Circulationaha.113.003192 |
0.67 |
|
| 2013 |
Ghosh AK, Murphy SB, Kishore R, Vaughan DE. Global gene expression profiling in PAI-1 knockout murine heart and kidney: molecular basis of cardiac-selective fibrosis. Plos One. 8: e63825. PMID 23724005 DOI: 10.1371/Journal.Pone.0063825 |
0.33 |
|
| 2012 |
Muldowney JA, Chen Q, Blakemore DL, Vaughan DE. Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: a pilot study. Angiology. 63: 429-34. PMID 22345157 DOI: 10.1177/0003319712436755 |
0.314 |
|
| 2012 |
Lee SH, Eren M, Vaughan DE, Schleimer RP, Cho SH. A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma. American Journal of Respiratory Cell and Molecular Biology. 46: 842-6. PMID 22323366 DOI: 10.1165/Rcmb.2011-0369Oc |
0.337 |
|
| 2012 |
Ghosh AK, Nagpal V, Covington JW, Michaels MA, Vaughan DE. Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT. Cellular Signalling. 24: 1031-6. PMID 22245495 DOI: 10.1016/J.Cellsig.2011.12.024 |
0.3 |
|
| 2012 |
Ghosh AK, Vaughan DE. Fibrosis: is it a coactivator disease? Frontiers in Bioscience (Elite Edition). 4: 1556-70. PMID 22201975 DOI: 10.2741/480 |
0.329 |
|
| 2012 |
Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. Journal of Cellular Physiology. 227: 493-507. PMID 21465481 DOI: 10.1002/Jcp.22783 |
0.319 |
|
| 2011 |
Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE, Smith LH. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. Journal of Hypertension. 29: 724-31. PMID 21358420 DOI: 10.1097/Hjh.0B013E32834347De |
0.666 |
|
| 2011 |
Agirbasli M, Eren M, Eren F, Murphy SB, Serdar ZA, Seckin D, Zara T, Cem Mat M, Demirkesen C, Vaughan DE. Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. Journal of Thrombosis and Thrombolysis. 32: 59-63. PMID 21311952 DOI: 10.1007/S11239-011-0556-Y |
0.34 |
|
| 2010 |
Ghosh AK, Bradham WS, Gleaves LA, De Taeye B, Murphy SB, Covington JW, Vaughan DE. Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. Circulation. 122: 1200-9. PMID 20823384 DOI: 10.1161/Circulationaha.110.955245 |
0.392 |
|
| 2010 |
De Taeye BM, Morisseau C, Coyle J, Covington JW, Luria A, Yang J, Murphy SB, Friedman DB, Hammock BB, Vaughan DE. Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring, Md.). 18: 489-98. PMID 19644452 DOI: 10.1038/Oby.2009.227 |
0.309 |
|
| 2008 |
Schoenhard JA, Asselbergs FW, Poku KA, Stocki SA, Gordon S, Vaughan DE, Brown NJ, Moore JH, Williams SM. Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population. Human Genetics. 124: 479-88. PMID 18953568 DOI: 10.1007/S00439-008-0573-X |
0.718 |
|
| 2008 |
Cleator JH, Vaughan DE. Clinical implications of the contrasting effects of in vivo thrombin receptor activation (protease-activated receptor type 1) on the human vasculature. Journal of the American College of Cardiology. 51: 1757-9. PMID 18452781 DOI: 10.1016/J.Jacc.2008.01.037 |
0.331 |
|
| 2008 |
Khoo MS, Grueter CE, Eren M, Yang J, Zhang R, Bass MA, Lwin ST, Mendes LA, Vaughan DE, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein. Journal of Molecular and Cellular Cardiology. 44: 405-10. PMID 18048055 DOI: 10.1016/J.Yjmcc.2007.10.014 |
0.319 |
|
| 2007 |
Vaughan DE, De Taeye BM, Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Current Drug Targets. 8: 962-70. PMID 17896947 DOI: 10.2174/138945007781662364 |
0.344 |
|
| 2007 |
Nordstrom SM, Carleton SM, Carson WL, Eren M, Phillips CL, Vaughan DE. Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization. Bone. 41: 995-1004. PMID 17888748 DOI: 10.1016/J.Bone.2007.08.020 |
0.764 |
|
| 2007 |
Schoenhard JA, Muldowney JA, Emens JS, Lewy AJ, Vaughan DE. Plasminogen activator inhibitor-1 has a circadian rhythm in blind individuals. Thrombosis and Haemostasis. 98: 479-81. PMID 17721638 DOI: 10.1160/Th06-12-0696 |
0.728 |
|
| 2007 |
Devin JK, Johnson JE, Eren M, Gleaves LA, Bradham WS, Bloodworth JR, Vaughan DE. Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. Journal of Molecular Endocrinology. 39: 9-16. PMID 17601881 DOI: 10.1677/Jme-06-0057 |
0.384 |
|
| 2007 |
Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Snieder H, Navis G, Vaughan DE, van Gilst WH, Moore JH. The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context. Human Genetics. 122: 275-81. PMID 17593394 DOI: 10.1007/S00439-007-0400-9 |
0.318 |
|
| 2007 |
Devin JK, Blevins LS, Verity DK, Chen Q, Bloodworth JR, Covington J, Vaughan DE. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. The Journal of Clinical Endocrinology and Metabolism. 92: 3633-9. PMID 17579195 DOI: 10.1210/Jc.2007-0609 |
0.355 |
|
| 2007 |
Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, Vaughan DE. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. Journal of Thrombosis and Haemostasis : Jth. 5: 1500-8. PMID 17439629 DOI: 10.1111/J.1538-7836.2007.02587.X |
0.392 |
|
| 2007 |
Brown NJ, Bradford J, Wang Z, Lea W, Ma L, Ma J, Vaughan DE, Fogo AB. Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency. Kidney International. 72: 72-81. PMID 17429342 DOI: 10.1038/Sj.Ki.5002268 |
0.364 |
|
| 2007 |
Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH. Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics. 89: 362-9. PMID 17207964 DOI: 10.1016/J.Ygeno.2006.11.004 |
0.361 |
|
| 2007 |
Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH. Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. Journal of Thrombosis and Haemostasis : Jth. 5: 313-20. PMID 17092303 DOI: 10.1111/J.1538-7836.2007.02311.X |
0.316 |
|
| 2007 |
Bradham W, Gleaves L, Medda M, Vaughan D. Plasminogen Activator Inhibitor-1 Deficiency and Aging Contribute to Upregulation of Profibrotic Pathways, Cardiac Fibrosis, and Alterations of Myocardial Function in Mice Journal of Cardiac Failure. 13: S71. DOI: 10.1016/J.Cardfail.2007.06.312 |
0.364 |
|
| 2006 |
De Taeye BM, Novitskaya T, Gleaves L, Covington JW, Vaughan DE. Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. The Journal of Biological Chemistry. 281: 32796-805. PMID 16931518 DOI: 10.1074/Jbc.M606214200 |
0.307 |
|
| 2006 |
Murphey LJ, Malave HA, Petro J, Biaggioni I, Byrne DW, Vaughan DE, Luther JM, Pretorius M, Brown NJ. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. The Journal of Pharmacology and Experimental Therapeutics. 318: 1287-92. PMID 16772538 DOI: 10.1124/Jpet.106.104026 |
0.303 |
|
| 2006 |
Vaughan DE. PAI-1 and TGF-beta: unmasking the real driver of TGF-beta-induced vascular pathology. Arteriosclerosis, Thrombosis, and Vascular Biology. 26: 679-80. PMID 16556860 DOI: 10.1161/01.Atv.0000209949.86606.C2 |
0.349 |
|
| 2006 |
Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney International. 69: 1064-72. PMID 16528256 DOI: 10.1038/Sj.Ki.5000201 |
0.34 |
|
| 2006 |
Brown NJ, Muldowney JA, Vaughan DE. Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition. Hypertension. 47: 441-8. PMID 16432054 DOI: 10.1161/01.Hyp.0000202478.79587.1A |
0.341 |
|
| 2006 |
Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, Washington K, Vaughan DE. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood. 107: 132-4. PMID 16160004 DOI: 10.1182/Blood-2005-07-2681 |
0.685 |
|
| 2006 |
Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, Gilst WHv, Moore JH. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thrombosis and Haemostasis. 96: 471-477. DOI: 10.1160/Th06-06-0335 |
0.333 |
|
| 2005 |
Vaughan DE. PAI-1 and atherothrombosis. Journal of Thrombosis and Haemostasis : Jth. 3: 1879-83. PMID 16102055 DOI: 10.1111/J.1538-7836.2005.01420.X |
0.367 |
|
| 2005 |
McLaughlin JN, Mazzoni MR, Cleator JH, Earls L, Perdigoto AL, Brooks JD, Muldowney JA, Vaughan DE, Hamm HE. Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells. The Journal of Biological Chemistry. 280: 22172-80. PMID 15817447 DOI: 10.1074/Jbc.M500721200 |
0.335 |
|
| 2005 |
De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Current Opinion in Pharmacology. 5: 149-54. PMID 15780823 DOI: 10.1016/J.Coph.2005.01.007 |
0.654 |
|
| 2005 |
Lin Z, Kumar A, SenBanerjee S, Staniszewski K, Parmar K, Vaughan DE, Gimbrone MA, Balasubramanian V, GarcÃa-Cardeña G, Jain MK. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circulation Research. 96: e48-57. PMID 15718498 DOI: 10.1161/01.Res.0000159707.05637.A1 |
0.346 |
|
| 2005 |
Smith LH, Petrie MS, Morrow JD, Oates JA, Vaughan DE. The sterol response element binding protein regulates cyclooxygenase-2 gene expression in endothelial cells. Journal of Lipid Research. 46: 862-71. PMID 15716578 DOI: 10.1194/Jlr.M500021-Jlr200 |
0.668 |
|
| 2005 |
Shaklee JF, Talbot TR, Muldowney JA, Vaughan DE, Butler J, House F, Crowe JE, Smith LH, Edwards KM. Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events. The Journal of Infectious Diseases. 191: 724-30. PMID 15688286 DOI: 10.1086/427831 |
0.628 |
|
| 2005 |
Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology. 25: 365-71. PMID 15576638 DOI: 10.1161/01.Atv.0000152356.85791.52 |
0.33 |
|
| 2004 |
Pretorius M, McFarlane JA, Vaughan DE, Brown NJ, Murphey LJ. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass. Clinical Pharmacology and Therapeutics. 76: 379-87. PMID 15470338 DOI: 10.1016/J.Clpt.2004.06.004 |
0.317 |
|
| 2004 |
Smith LH, Coats SR, Qin H, Petrie MS, Covington JW, Su M, Eren M, Vaughan DE. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. Circulation Research. 95: 269-75. PMID 15217907 DOI: 10.1161/01.Res.0000136521.70093.F1 |
0.676 |
|
| 2004 |
Coffey CS, Hebert PR, Ritchie MD, Krumholz HM, Gaziano JM, Ridker PM, Brown NJ, Vaughan DE, Moore JH. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. Bmc Bioinformatics. 5: 49. PMID 15119966 DOI: 10.1186/1471-2105-5-49 |
0.301 |
|
| 2004 |
Hou B, Eren M, Painter CA, Covington JW, Dixon JD, Schoenhard JA, Vaughan DE. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. The Journal of Biological Chemistry. 279: 18127-36. PMID 14963043 DOI: 10.1074/Jbc.M310438200 |
0.743 |
|
| 2004 |
Muldowney JA, Roberts BC, Covington JW, Schoenhard JA, Brown NJ, Vaughan DE. 1007-182 Aldosterone and plasma renin activity influence plasma plasminogen activato inhibitor-1 levels in overweight subjects Journal of the American College of Cardiology. 43: A445. DOI: 10.1016/S0735-1097(04)91875-X |
0.714 |
|
| 2003 |
Pretorius M, Murphey LJ, McFarlane JA, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass. Circulation. 108: 3079-83. PMID 14656921 DOI: 10.1161/01.Cir.0000105765.54573.60 |
0.336 |
|
| 2003 |
Eren M, Painter CA, Gleaves LA, Schoenhard JA, Atkinson JB, Brown NJ, Vaughan DE. Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice. Journal of Thrombosis and Haemostasis : Jth. 1: 2389-96. PMID 14629474 DOI: 10.1046/J.1538-7836.2003.00437.X |
0.75 |
|
| 2003 |
Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. The Journal of Clinical Endocrinology and Metabolism. 88: 3867-73. PMID 12915681 DOI: 10.1210/Jc.2003-030374 |
0.319 |
|
| 2003 |
Vaughan DE. Plasminogen activator inhibitor-1 and the calculus of mortality after myocardial infarction. Circulation. 108: 376-7. PMID 12885727 DOI: 10.1161/01.Cir.0000082929.85234.E7 |
0.338 |
|
| 2003 |
Schoenhard JA, Smith LH, Painter CA, Eren M, Johnson CH, Vaughan DE. Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. Journal of Molecular and Cellular Cardiology. 35: 473-81. PMID 12738229 DOI: 10.1016/S0022-2828(03)00051-8 |
0.77 |
|
| 2003 |
Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 107: 579-85. PMID 12566370 DOI: 10.1161/01.Cir.0000046268.59922.A4 |
0.305 |
|
| 2003 |
Muldowney JA, Falck JR, Brown NJ, Vaughan DE. The role of endothelial-derived hyperpolarizing factor in tissue-type plasminogen activator release Journal of the American College of Cardiology. 41: 233. DOI: 10.1016/S0735-1097(03)81667-4 |
0.31 |
|
| 2002 |
Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension. 40: 859-65. PMID 12468570 DOI: 10.1161/01.Hyp.0000040264.15961.48 |
0.321 |
|
| 2002 |
Srikumar N, Brown NJ, Hopkins PN, Jeunemaitre X, Hunt SC, Vaughan DE, Williams GH. PAI-1 in human hypertension: relation to hypertensive groups. American Journal of Hypertension. 15: 683-90. PMID 12160190 DOI: 10.1016/S0895-7061(02)02952-7 |
0.312 |
|
| 2002 |
Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 106: 491-6. PMID 12135951 DOI: 10.1161/01.Cir.0000023186.60090.Fb |
0.361 |
|
| 2002 |
Moore JH, Smolkin ME, Lamb JM, Brown NJ, Vaughan DE. The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms. Clinical Genetics. 62: 53-9. PMID 12123488 DOI: 10.1034/J.1399-0004.2002.620107.X |
0.32 |
|
| 2002 |
Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, ... ... Vaughan D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy. 16: 149-60. PMID 12090908 DOI: 10.1023/A:1015709617405 |
0.338 |
|
| 2002 |
Smith LH, Boutaud O, Breyer M, Morrow JD, Oates JA, Vaughan DE. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arteriosclerosis, Thrombosis, and Vascular Biology. 22: 983-8. PMID 12067908 DOI: 10.1161/01.Atv.0000019734.89917.35 |
0.669 |
|
| 2002 |
Schoenhard JA, Eren M, Johnson CH, Vaughan DE. Alternative splicing yields novel BMAL2 variants: tissue distribution and functional characterization. American Journal of Physiology. Cell Physiology. 283: C103-14. PMID 12055078 DOI: 10.1152/Ajpcell.00541.2001 |
0.728 |
|
| 2002 |
Kaikita K, Schoenhard JA, Painter CA, Ripley RT, Brown NJ, Fogo AB, Vaughan DE. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. Journal of Molecular and Cellular Cardiology. 34: 617-27. PMID 12054849 DOI: 10.1006/Jmcc.2002.2001 |
0.754 |
|
| 2002 |
Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. The Journal of Clinical Endocrinology and Metabolism. 87: 448-52. PMID 11836266 DOI: 10.1210/Jcem.87.2.7980 |
0.335 |
|
| 2002 |
Vaughan DE. Angiotensin and vascular fibrinolytic balance. American Journal of Hypertension. 15: 3S-8S. PMID 11824873 DOI: 10.1016/S0895-7061(01)02273-7 |
0.362 |
|
| 2002 |
Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation. 105: 304-9. PMID 11804984 DOI: 10.1161/Hc0302.102570 |
0.732 |
|
| 2002 |
Schoenhard JA, Vaughan DE. Transforming growth factor-b regulation of plasminogen activator inhibitor-1 gene expression at the 4G/5G polymorphism Journal of the American College of Cardiology. 39: 203-204. DOI: 10.1016/S0735-1097(02)80901-9 |
0.716 |
|
| 2001 |
Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, ... ... Vaughan D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. The American Journal of Cardiology. 88: 1L-20L. PMID 11694220 DOI: 10.1016/S0002-9149(01)01878-1 |
0.341 |
|
| 2001 |
Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 104: 839-44. PMID 11502712 DOI: 10.1161/Hc3301.092803 |
0.729 |
|
| 2001 |
Vaughan DE. Angiotensin, fibrinolysis, and vascular homeostasis. The American Journal of Cardiology. 87: 18C-24C. PMID 11334764 DOI: 10.1016/S0002-9149(01)01509-0 |
0.328 |
|
| 2001 |
Coats SR, Covington JW, Su M, Pabón-Peña LM, Eren M, Hao Q, Vaughan DE. SSeCKS gene expression in vascular smooth muscle cells: regulation by angiotensin II and a potential role in the regulation of PAI-1 gene expression. Journal of Molecular and Cellular Cardiology. 32: 2207-19. PMID 11112996 DOI: 10.1006/Jmcc.2000.1246 |
0.338 |
|
| 2000 |
Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney International. 58: 1219-27. PMID 10972684 DOI: 10.1046/J.1523-1755.2000.00277.X |
0.377 |
|
| 2000 |
Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney International. 58: 251-9. PMID 10886570 DOI: 10.1046/J.1523-1755.2000.00160.X |
0.37 |
|
| 2000 |
Vaughan DE. AT1 receptor blockade and atherosclerosis: Hopeful insights into vascular protection Circulation. 101: 1496-1497. PMID 10747338 DOI: 10.1161/01.Cir.101.13.1496 |
0.301 |
|
| 2000 |
Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. The Journal of Clinical Endocrinology and Metabolism. 85: 336-44. PMID 10634408 DOI: 10.1210/Jcem.85.1.6305 |
0.349 |
|
| 1999 |
Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension (Dallas, Tex. : 1979). 34: 285-90. PMID 10454455 DOI: 10.1161/01.Hyp.34.2.285 |
0.359 |
|
| 1999 |
Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension (Dallas, Tex. : 1979). 33: 1431-5. PMID 10373228 DOI: 10.1161/01.Hyp.33.6.1431 |
0.304 |
|
| 1999 |
Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension (Dallas, Tex. : 1979). 32: 965-71. PMID 9856958 DOI: 10.1161/01.Hyp.32.6.965 |
0.343 |
|
| 1999 |
Brown NJ, Vaughan DE. Role of angiotensin II in coagulation and fibrinolysis Heart Failure Reviews. 3: 193-198. DOI: 10.1023/A:1009757416302 |
0.364 |
|
| 1998 |
Roselli HT, Su M, Washington K, Kerins DM, Vaughan DE, Russell WE. Liver regeneration is transiently impaired in urokinase-deficient mice. The American Journal of Physiology. 275: G1472-9. PMID 9843786 DOI: 10.1152/Ajpgi.1998.275.6.G1472 |
0.704 |
|
| 1998 |
Stein CM, Brown N, Vaughan DE, Lang CC, Wood AJ. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. Journal of the American College of Cardiology. 32: 117-22. PMID 9669258 DOI: 10.1016/S0735-1097(98)00210-1 |
0.324 |
|
| 1998 |
Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. The Journal of Biological Chemistry. 273: 18268-72. PMID 9660790 DOI: 10.1074/Jbc.273.29.18268 |
0.318 |
|
| 1998 |
Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors Circulation. 97: 1411-1420. PMID 9577953 DOI: 10.1161/01.Cir.97.14.1411 |
0.338 |
|
| 1997 |
Vaughan DE. The renin-angiotensin system and fibrinolysis American Journal of Cardiology. 79: 12-16. PMID 9127616 DOI: 10.1016/S0002-9149(97)00124-0 |
0.375 |
|
| 1997 |
Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney International. 51: 164-72. PMID 8995730 DOI: 10.1038/Ki.1997.20 |
0.367 |
|
| 1997 |
Vaughan DE, Rouleau JL, Pfeffer MA. Role of the fibrinolytic system in preventing myocardial infarction. European Heart Journal. 31-6. PMID 8869133 DOI: 10.1093/Eurheartj/16.Suppl_K.31 |
0.302 |
|
| 1997 |
Ridker PM, Baker MT, Hennekens CH, Stampfer MJ, Vaughan DE. Alu-repeat Polymorphism in the Gene Coding for Tissue-Type Plasminogen Activator (t-PA) and Risks of Myocardial Infarction Among Middle-aged Men Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 1687-1690. DOI: 10.1161/Atvb.17V09.1687 |
0.319 |
|
| 1997 |
Brown NJ, Nadeau JH, Vaughan DE. Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin Thrombosis and Haemostasis. 77: 522-525. DOI: 10.1055/S-0038-1656000 |
0.338 |
|
| 1997 |
Venkov C, Su M, Shyr Y, Vaughan D. Ethanol-induced alterations in the expression of endothelial-derived fibrinolytic components Fibrinolysis and Proteolysis. 11: 115-118. DOI: 10.1016/S0268-9499(97)80104-X |
0.314 |
|
| 1996 |
Lee E, Vaughan DE, Parikh SH, Grodzinsky AJ, Libby P, Lark MW, Lee RT. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circulation Research. 78: 44-9. PMID 8603504 DOI: 10.1161/01.Res.78.1.44 |
0.311 |
|
| 1996 |
Brown NJ, Vaughan DE. The renin-angiotensin and fibrinolytic systems: Co-conspirators in the pathogenesis of ischemic cardiovascular disease Trends in Cardiovascular Medicine. 6: 239-243. DOI: 10.1016/S1050-1738(96)00091-6 |
0.332 |
|
| 1995 |
Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. The Journal of Clinical Investigation. 95: 995-1001. PMID 7884001 DOI: 10.1172/Jci117809 |
0.355 |
|
| 1995 |
Simon DI, Xu H, Vaughan DE. Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes. Biochimica Et Biophysica Acta. 1268: 143-51. PMID 7662701 DOI: 10.1016/0167-4889(95)00063-X |
0.32 |
|
| 1995 |
Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV Journal of Clinical Investigation. 96: 2515-2520. PMID 7593643 DOI: 10.1172/Jci118312 |
0.317 |
|
| 1995 |
Vaughan DE. Plasminogen activator inhibitor 1: Molecular aspects and clinical importance Journal of Thrombosis and Thrombolysis: An International Journal For Clinicians and Scientists. 2: 187-193. DOI: 10.1007/Bf01062709 |
0.368 |
|
| 1994 |
Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. Jama. 272: 929-33. PMID 7794308 DOI: 10.1001/Jama.1994.03520120039028 |
0.3 |
|
| 1993 |
Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 87: 1969-73. PMID 8504511 DOI: 10.1161/01.Cir.87.6.1969 |
0.323 |
|
| 1993 |
Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet (London, England). 341: 1165-8. PMID 8098074 DOI: 10.1016/0140-6736(93)90998-V |
0.309 |
|
| 1992 |
Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis: A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor Circulation. 85: 1822-1827. PMID 1572039 DOI: 10.1161/01.Cir.85.5.1822 |
0.357 |
|
| 1992 |
Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactivated Recombinant Plasminogen Activator Inhibitor-1 (rPAI-1) Effectively Prevents Thrombolysis In Vivo Thrombosis and Haemostasis. 68: 060-063. DOI: 10.1055/S-0038-1656318 |
0.355 |
|
| 1990 |
Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circulation Research. 67: 1281-6. PMID 2225359 DOI: 10.1161/01.Res.67.5.1281 |
0.356 |
|
| 1990 |
Vaughan DE, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. The American Journal of Cardiology. 66: 529-32. PMID 1975472 DOI: 10.1016/0002-9149(90)90476-H |
0.303 |
|
| 1989 |
Vaughan DE, Declerck PJ, De Mol M, Collen D. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. The Journal of Clinical Investigation. 84: 586-91. PMID 2503540 DOI: 10.1172/Jci114202 |
0.333 |
|
| 1989 |
Vaughan D, Plavin S, Schafer A, Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator Blood. 73: 1213-1217. DOI: 10.1182/Blood.V73.5.1213.Bloodjournal7351213 |
0.337 |
|
| Show low-probability matches. |